Satellos Bioscience Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
MSLE Nasdaq 2830 satellos.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Satellos Bioscience Inc.

Satellos to Participate in Upcoming Investor Conferences - Oct 21st, 2026 5:00 am
Satellos Granted Composition of Matter Patent for Forazapadin - Oct 5th, 2026 5:00 am
Satellos Bioscience Completes Enrollment in Phase 2 Basecamp Trial - Sep 30th, 2026 12:00 pm
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy - Sep 30th, 2026 5:00 am
Satellos Receives FDA Clearance For FSHD Investigational New Drug Application - Sep 24th, 2026 10:32 am
Satellos Receives FDA Clearance to Study Forazapadin in FSHD - Sep 24th, 2026 7:59 am
Satellos stock jumps after FDA clears FSHD trial for forazapadin - Sep 24th, 2026 7:54 am
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development - Sep 24th, 2026 5:00 am
Satellos to Present at the 31st Annual Congress of the World Muscle Society - Sep 15th, 2026 5:00 am
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 - Sep 9th, 2026 5:00 am
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress - Aug 13th, 2026 3:02 pm
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update - Jul 10th, 2026 1:02 pm
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence - Jul 8th, 2026 7:34 am
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 - Jul 8th, 2026 4:30 am
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy - Jun 29th, 2026 5:00 am
Satellos to Present Clinical Program Updates at ICNMD 2026 - Jun 25th, 2026 5:00 am
Satellos Bioscience Announces Results of Annual Meeting of Shareholders - Jun 17th, 2026 3:00 pm
We're Not Very Worried About Satellos Bioscience's (TSE:MSCL) Cash Burn Rate - May 18th, 2026 7:36 am